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Summary  Head  and  neck  cancer  is  frequent  worldwide  and  oropharyngeal  locations  are
presently  sharply  on  the  increase,  in  relation  with  an  increasing  incidence  of  oropharyngeal
infection by  oncogenic  type-16  human  papillomavirus  (HPV).  The  clinical  and  biologic  proﬁle
of these  patients  is  distinct  from  that  of  other  oropharyngeal  carcinoma  patients,  with  earlier
onset, cystic  cervical  nodes  and  basaloid  carcinoma  histopathology.  Detection  of  intratumoral
viral DNA  is  essential  to  conﬁrm  the  role  of  HPV,  and  E6/E7  mRNA  expression  is  the  most  relevant
indicator for  stratiﬁcation.  Several  methods  can  reveal  intratumoral  oncogenic  HPV  DNA,  but
PCR with  hybridization  is  the  most  sensitive  and  most  widely  used.  According  to  several  reports,
prognosis in  terms  of  survival  and  locoregional  control  is  better  in  HPV-positive  oropharyngeal
carcinoma  than  in  oropharyngeal  carcinoma  associated  with  smoking  and  alcohol  consump-
tion. The  future  lies  in  vaccination,  but  further  studies  will  determine  whether  the  rate  of
oropharyngeal  carcinoma  falls  in  women  vaccinated  against  cervical  cancer.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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ead  and  neck  carcinoma  is  frequent,  with  the  sixth  highest
ncidence  of  all  locations,  worldwide.  In  France,  inci-
ence  in  2007  was  14,697  (11,158  in  males),  ranking  it  in
ourth  place  [http://globocan.iarc.fr], with  36,268  hospi-
al  admissions  [1].  Ninety-ﬁve  percent  are  squamous  cell
arcinomas.  Alcohol  consumption  and  smoking  are  usually
ssociated.  Prognosis  is  poor,  with  a  risk  of  locoregional
ailure  in  advanced  stages  (III,  IVa).  In  recent  years,  many
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oi:10.1016/j.anorl.2011.05.004tudies  have  shown  that  some  25%  of  oropharyngeal  car-
inomas  are  associated  with  oncogenic  or  high-risk  human
apillomavirus  (HPV),  already  widely  implicated  in  cervi-
al  carcinoma  [2—4]. HPV16  is  the  genotype  implicated
n  some  90%  of  high-risk  HPV  oropharyngeal  carcinomas,
s  compared  to  only  50%  of  cervical  carcinomas  [5].  The
ncidence  of  head  and  neck  carcinoma  associated  with  alco-
ol  consumption  and  smoking  is  falling  or  stabilizing  in
estern  countries,  but  oropharyngeal  carcinoma  related
o  HPV  is  increasing  so  regularly  that  some  speak  of  an
‘epidemic’’  [6—10]. Registry  studies  in  the  US  and  Scan-
inavia  reported  increases  of  2.1%  to  3.9%  per  year  in  the
requency  of  oropharyngeal  cancer  between  1973  and  2001,
ith  hypopharyngeal  and  laryngeal  cancer  rates  diminishing
8,10].
served.
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Clinico-epidemiological proﬁle of HPV-positive
head and neck cancers
Notable  features  have  been  reported  in  head  and  neck
cancer  according  to  HPV  status.  Histopathologically,  HPV-
positive  head  and  neck  cancer  tends  to  be  less  differentiated
and  of  basaloid  type.  Oropharyngeal  cancer,  involving
tonsils,  tongue-base,  soft  palate  or  pharyngeal  wall,  is
frequently  HPV-associated,  while  laryngeal  and  hypopha-
ryngeal  locations  are  strongly  associated  with  smoking  and
alcohol  addiction  [5,7]. This  prime  risk  factor  in  HPV-
negative  oropharyngeal  cancer  is  less  frequently  found  in
HPV-positive  forms,  this  trend  being  signiﬁcant  in  the  case  of
alcohol.  Possible  synergy  between  HPV  and  alcohol  consump-
tion  and  smoking  remains  controversial  [4,11,12].  According
to  Ang’s  team  [13], survival  in  smokers  with  HPV-positive
oropharyngeal  cancer  is  lower  than  in  HPV-positive  non-
smokers;  likewise,  HPV-negative  patients’  survival  is  better
in  case  of  non-smoking.  Smoking  seems  to  be  an  independent
risk  factor.  HPV-positive  oropharyngeal  cancer  patients  are
generally  5—10  years  younger  than  HPV-negative  patients.
Several  studies  have  demonstrated  a  relation  between
these  cancers  and  certain  forms  of  sexual  behavior:  early
ﬁrst  sexual  relations,  history  of  genital  warts,  infrequent
condom  use,  number  of  sexual  partners  and  oral  sexual
practices  [4,14]. Some  authors  consider  that  change  in
sexual  behavioral  patterns  has  contributed  to  the  rise  in
HPV  oropharyngeal  cancer  in  the  younger  population  [15].
Women  with  history  of  in  situ  carcinoma  or  cervical  cancer
and  their  partners  also  show  elevated  risk  of  HPV-positive
oropharyngeal  cancer,  suggesting  orogenital  transmission,
without  necessarily  excluding  transmission  by  oral  contact
[16].
Unlike  cervical  cancer,  exclusively  implicating  high-risk
HPV,  only  some  head  and  neck  cancers  are  HPV-associated.
A  recent  systematic  review  of  60  studies  estimated  a  25.9%
overall  prevalence  of  high-risk  HPV  DNA  in  head  and  neck
cancer  as  a  whole  [3].  Prevalence  was  signiﬁcantly  higher
(36%)  in  oropharyngeal  cancer,  and  could  exceed  50%,  espe-
cially  in  tonsillar  locations.  Prevalence  was  23.5%  in  oral
cavity  cancer  and  24%  in  laryngeal  cancer.  A  retrospective
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Table  1  Main  characteristics  of  HPV-positive  and  negative  patien
HPV-positive  
Biology  p53:  increased  catabolism  (E6)  
pRb: increased  catabolism  (E7)  
Abnormal  p16INK4a expression  
Age Younger  patients  (45—55  years)  
Performance  status  Good  
Risk factors  Sexual:  number  of  partners,  early
sexual  relations,  oral  sex
Adenopathy  Cystic  
Anatomopathology  Poorly  differentiated  or  basaloid
squamous  cell  carcinoma
Prognosis ‘‘Good’’  e27
tudy  (EDiTH  VI)  of  523  parafﬁn-embedded  oropharyngeal
nd  oral  cavity  cancer  samples  from  12  centers  located  all
ver  France  reported  an  HPV  prevalence  of  46.5%  for  the
ropharynx  and  10.5%  for  the  oral  cavity  [17]; it  reached
7%  for  tonsillar  cancer  [18], comparable  to  other  reports
or  this  location.
Genotype  detection  and  identiﬁcation  is  based  on  tech-
iques  that  have  evolved  over  time,  which  partly  accounts
or  differences  in  literature  reports,  which  also,  however,
eﬂect  geographic  variations  in  risk  factors.  The  latter  were
emonstrated  in  a  report  of  two  case-control  studies  in  Cen-
ral  European  and  Latin  American  populations,  where  the
moking/alcohol  risk  factor  predominates  [19]: HPV16  DNA
revalence  was  very  low  (4.4%  in  oropharyngeal  cancer),
espite  the  high-incidence  of  head  and  neck  cancer  in  these
egions.
HPV-positive  oropharyngeal  squamous  cell  carcinoma
hus  presents  speciﬁc  characteristics,  and  represents  an
riginal  entity  among  head  and  neck  cancers  (Table  1).
irology and pathogenesis
PV  is  an  environment-resistant  species-speciﬁc  epithe-
iotropic  non-enveloped  DNA  virus  [20]. It  is  implicated  in
 wide  range  of  frequent  and  usually  benign  cutaneous  and
ucosal  lesions.  About  120  genotypes  have  been  described,
ncluding  some  40  liable  to  infect  mucosa  and  at  least  15
ssociated  to  precancerous  and  cancerous  anogenital  and
pper  aerodigestive  tract  mucosal  lesions.  HPV  16  accounts
or  85—95%  of  HPVs  detected  in  HPV-positive  oropharyngeal
umors,  other  genotypes  (notably,  HPV  18  and  31)  account-
ng  for  less  than  10%  [5].  In  the  French  EDiTH  VI  study  [17],
PV16  was  reported  in  89.7%  of  oropharyngeal  cancers  (89%
or  tonsillar  locations),  and  95.5%  of  oral  cavity  cancers.
Presently,  the  role  of  high-risk  HPV  is  best  proven  in  cervi-
al  carcinoma.  Viral  DNA  is  almost  systematically  detected,
nd  persistent  high-risk  HPV  infection  of  the  cervix  is  the
ain  risk  factor  for  oncologic  evolution,  especially  when
he  HPV16  genotype  is  implicated.  Cervical  cancer  is  now
onsidered  by  the  WHO  as  being  virus-induced,  although
iral  infection  is  not  a  sufﬁcient  condition.  In  vitro,  high-risk
ts.
HPV-negative
p53  inactivation  by  mutation
No  pRb  degradation
p16INK4a -CyclineD1/CDK-pRb  pathway
deactivated:  p16INK4a not  expressed
Elderly  (55—65  years)
Poor
 ﬁrst Alcohol/smoking
Tissular
Moderately  or  well  differentiated
squamous  cell  carcinoma
Poor
e28  
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to  HPV-negative  oropharyngeal  cancer  [30,31].  Deletionsigure  1  Schema  of  HPV16  genome.  E:  early  region;  L:  late
egion; LCR:  long  control  region.
PV  can  immortalize  primary  keratinocytes,  whether  from
he  cervix,  foreskin  or  tonsillar  epithelium,  but  transforma-
ion  occurs  only  after  repeated  passages  or  co-expression  of
nother  oncogene:  i.e.,  additional  events  are  necessary  for
 transformed  phenotype  to  appear  [21,22].
It  is  indispensable  to  detect  viral  DNA  within  the  tumor  to
onﬁrm  the  role  of  HPV  in  oncogenesis.  E6/E7  mRNA,  how-
ver,  is  a  more  relevant  indicator  for  stratiﬁcation  [23,24].
n  cervical  cancer,  the  E6  and  E7  genes  are  transcribed,  and
n  vitro  studies  suggest  that  their  expression  is  a  prerequisite
n  maintaining  the  transformed  phenotype.  The  same  ﬁnd-
ngs  would  seem  to  apply  in  HPV  oropharyngeal  carcinoma,
lthough  studies  are  as  yet  rare  [23,25].
E6  and  E7  proteins  are  coded  by  a  particular,  so-called
‘early’’,  region  of  the  viral  genome  (Fig.  1).  They  underlie
he  oncogenic  properties  of  high-risk  HPV.  Their  functions
ainly  depend  on  their  interaction  with  numerous  cellular
egulatory  and  signalling  pathways  involved  in  cell  prolifera-
ion,  apoptosis,  DNA  repair  and  gene  stability,  transcription
egulation,  cell  polarity,  angiogenesis  and  immune  response,
hus  mimicking  most  of  the  effects  of  gene  alterations  in
ther  forms  of  cancer  [21,22].  The  cell  cycle  regulation
athways  are  a  prime  target  of  E6  and  E7  viral  proteins.
Rb  protein,  an  inhibitor  of  cell  cycle  progression  in  the  S-
hase  of  DNA  replication,  is  targeted  by  E7  and  degraded,
nducing  expression  of  p16INK4a,  another  cell  cycle  inhibitor,
ommonly  used  as  a  marker  for  high-risk  HPV,  although  actu-
lly  reﬂecting  a  consequence  of  E7  expression.  p53  protein,
ble  to  induce  cell  cycle  arrest  or  apoptosis  under  various
timulations  such  as  overexpression  of  an  oncogene  or  cel-
ular  DNA  abnormality,  is  degraded  via  E6,  mimicking  but
ot  equivalent  to  the  deactivating  mutations  of  p53  fre-
uently  found  in  HPV-negative  cancer,  as  E6  inhibition  (under
isplatin  treatment,  for  example)  restores  functional  p53,
hereas  mutated  p53  is  deﬁnitively  inactive.  In  summary,
he  properties  of  E6  and  E7  in  high-risk  HPV  promote  cell  sur-
ival  and  proliferation,  avoidance  of  immune  response  and
 genetic  instability  that  contributes  to  the  development  of
ancer.In  cervical  cancer,  viral  genome  integration  into  the
ell  genome  is  predominant  and  correlated  with  precan-
erous  lesion  progression,  but  is  not  a  precondition  for  the
a
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evelopment  of  cancer.  HPV16  viral  DNA  is  purely  episomal
n  up  to  a  quarter  of  cases.  In  oropharyngeal  carcinoma,
lthough  there  have  been  few  studies  and  some  of  these
ere  discordant,  integrated  forms  would  seem  to  be  equally
reponderant  [22,26,27].
The  mechanisms  of  viral  oncogenesis  in  the  oropharynx
re  probably  similar  to  those  of  cervical  cancer.  The  proper-
ies  of  E6  and  E7  seemed  similar  in  in  vitro  studies  of  genital
nd  of  oropharyngeal  keratinocytes  [22,23]. Differences
elated  to  the  anatomic,  cellular  and  immune  environment
nd  to  contact  with  exogenic  risk  factors  probably  play  a
ajor  role.  Moreover,  there  is  no  region  in  the  oropharynx
quivalent  to  the  uterine  cervix’s  junction  or  transformation
egion,  where  the  malpighian  epithelium  of  the  exocervix
oins  the  unistratiﬁed  glandular  epithelium  of  the  endo-
ervix  and  which  is  where  most  cancers  develop.  In  the
onsillar  crypts,  areas  of  malpighian  epithelium  alternate
ith  areas  of  specialized  reticulated  epithelium  associated
ith  interruptions  in  basement  continuity;  some  authors
uggest  that  the  crypts  are  preferentially  targeted,  enabling
nfection  to  endure  and  thus  possibly  accounting  for  the
reater  prevalence  of  HPV-positive  cancer  in  the  tonsils  as
ompared  to  other  head  and  neck  sites  [27,28].
tratiﬁcation of HPV head and neck cancers:
etection of direct and indirect virologic
arkers
here  are  several  methods  for  revealing  high-risk  HPV  DNA
n  tumor  tissue  [29]. One  of  the  earliest  to  be  mentioned
n  the  oropharyngeal  cancer  literature  is  in  situ  hybridiza-
ion,  using  speciﬁc  probes  to  determine  the  cellular  location
f  the  viral  DNA.  However,  PCR  (polymerase  chain  reac-
ion)  followed  by  hybridization  with  dedicated  probes  is
he  most  sensitive  and  widely  used  technique,  with  numer-
us  kits  on  the  market.  It  is  easy  to  perform  on  biopsy
amples  placed  in  transport  medium  or  directly  frozen.
t  can  be  performed  retrospectively  on  parafﬁn-embedded
issue,  but  with  lower  sensitivity  than  in  fresh  or  frozen
issue.  E6/E7  mRNA  induces  expression  of  viral  oncopro-
eins  and  is  the  most  informative  and  relevant  factor  for
tratifying  high-risk  HPV  cancers.  Samples  should  be  placed
n  media  enabling  conservation  of  the  labile  RNA,  which
annot  be  efﬁciently  detected  in  parafﬁn-embedded  sec-
ions.  Immunohistochemical  detection  of  p16INK4a protein
also  known  as  p16)  resulting  from  pRb  degradation  by  E7
ay  further  help  detection  of  DNA,  conﬁrming  the  associa-
ion  with  high-risk  HPV,  especially  in  patients  with  other  risk
actors  in  whom  mRNA  cannot  be  detected.  Several  studies
ave  shown  that  most  HPV  tumors  express  p16  [7];  but  it  is
o  be  borne  in  mind  that  some  p16-positive  tumors  can  be
PV-negative:  p16  detection  in  itself  does  not  reliably  diag-
ose  head  and  neck  cancer  associated  with  HPV,  and  needs
upplementing  by  viral  DNA  detection.
The  chromosomal  alteration  proﬁle  of  HPV-positive
ropharyngeal  cancer  seems  generally  similar  to  that  of
ervical  cancer,  but  shows  more  differences  with  respectnd  allele  loss  are  more  frequent  in  HPV-negative  tumor.
or  example,  deletion  at  3p  and  5q  and  ampliﬁcation  at
1q  is  frequent  only  in  HPV-negative  oropharyngeal  cancer
HPV  and  head  and  neck  cancer  e29
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Adapted  from  
(Fig.  2).  Expression  proﬁles  correlate  with  these  ﬁndings
[32].  Affected  regions  often  concern  genes  involved  in
cell  cycle  and  growth  [23]. Deactivation  of  p53-MDM2  and
p16INK4a-cyclin  D1/CDK4/6-pRb  pathways  is  common,  result-
ing  from  mutations,  deletions,  methylation  (9p21,  CDKN2A
coding  p16INK4a)  or  ampliﬁcation  (11q13,  CCND1  coding  cyclin
D1)  in  HPV-negative  cancer  or  from  expression  of  high-risk
E6  and  E7  (degradation  of  p53  and  pRb,  activation  of  CDK)
in  HPV-positive  cancer.
HPV status, prognosis and treatment response
Several  studies  showed  HPV  status  to  be  a  strong  inde-
pendent  prognostic  factor:  prognosis  in  terms  of  survival
and  locoregional  control  is  better  in  case  of  HPV-positive
oropharyngeal  carcinoma  [13,33].  Treatment  strategies
in  oropharyngeal  carcinoma  consist  in  various  associa-
tions  of  local  and  lymph-node  surgery,  radiation  therapy,
concomitant  radiochemotherapy,  induction  chemotherapy,
biotherapy  by  targeted  therapy  and  repair  surgery  [34,35].
Indications  follow  guidelines,  but  have  yet  to  take  account
of  HPV  status.  Comparative  studies  of  oropharyngeal  cancer
treatment  should  henceforth  include  stratiﬁcation  accord-
ing  to  HPV  status.
Patients  with  HPV-positive  oropharyngeal  carcinoma
show  better  treatment  response  to  induction  chemotherapy,
concomitant  radiochemotherapy  and  exclusive  radiation
therapy  than  HPV-negative  patients.  Fakhry  et  al.  [36]
reported  signiﬁcantly  higher  complete  and  partial  response
rates  following  induction  chemotherapy  (two  cycles  of
carboplatin  and  paclitaxel)  in  HPV-positive  than  neg-
ative  patients  (82%  versus  55%,  P  =  0.01).  HPV-positive
oropharyngeal  carcinoma  patients  treated  by  conventional
radiation  therapy  or  surgery  with  or  without  postoperative
a
s
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End  neck  oncogenesis.
ts  et  al.  [31].
adiation  therapy  also  showed  better  local  control  and
verall  recurrence-free  survival  than  HPV-negative  patients
37—39].  On  the  other  hand,  adding  a  molecule  promoting
issue  hypoxia  to  radiation  therapy  improved  local  control
nd  recurrence-free  survival  in  HPV-negative  but  not  HPV-
ositive  patients  [40].
Kumar  et  al.  [41]  reported  better  overall  and  speciﬁc  sur-
ival  in  HPV-positive  patients  with  low  as  compared  to  high
GFR  expression.  Smoking  induces  tissue  hypoxia  and  may
lso  increase  EGFR  expression.  Metachronic  tumor  is  also
igniﬁcantly  less  frequent  in  HPV-positive  patients  with  low
GFR  expression.  HPV  status  may  not,  however,  inﬂuence
ocal  control  and  recurrence-free  survival  under  accelerated
adiation  therapy  or  EGFR  inhibitors  [42].
he search for biomarkers
he  search  for  biomarkers  to  enable  ﬁne  prognostic  strat-
ﬁcation  and/or  treatment  optimization  is  an  essential
hallenge.  Some  teams  have  suggested  supplementary  strat-
ﬁcations  according  to  p53,  p16INK4A, EGFR,  cyclin  D1  or
21WAF1,  another  cell  cycle  inhibitor  [23,41,43,44]. Wild-
orm  p53  and  p16INK4A and  p21WAF1 expression  are  associated
ith  improved  prognosis.  A  Dutch  team  [45]  crossed  HPV
tatus  with  a  gene  expression  proﬁle  previously  shown  to
e  prognostic:  the  proﬁle  combined  with  HPV-negative  sta-
us  was  associated  with  elevated  risk  of  local  recurrence
fter  chemotherapy  in  advanced  cancer.  Further  large-scale
tudies  appear  necessary.
Various  viral  markers  may  be  prognostic  at  diagnosis
nd/or  follow-up  of  oropharyngeal  carcinoma,  as  demon-
trated  in  precancerous  and  cancerous  cervical  lesions.
he  impact  of  HPV  load  and  of  mRNA  coding  for  E6  and
7  detected  at  diagnosis  and  follow-up  on  recurrence  and
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urvival  remains  to  be  determined.  In  cervical  cancer,  HPV16
NA  in  pelvic  nodes  is  predictive  of  recurrence.  Viral  DNA
as  detected  in  cervical  nodes,  invaded  or  not,  in  oropha-
yngeal  carcinoma  patients,  but  its  prognostic  value  was
ot  investigated  [46]. Detecting  viral  DNA  or  E6/E7  mRNA
n  invaded  or  non-invaded  lymph-nodes  would  help  deter-
ine  the  prognostic  value.  Likewise,  in  the  uterine  cervix,
t  has  been  clearly  established  that  persistent  high-risk  HPV
nfection  is  predictive  of  progression  toward  high-grade  dys-
lasia  and  cancer,  especially  when  the  viral  load  is  elevated.
imilarly,  persistent  infection  after  conization  in  dyspla-
ia  or  radiation  therapy  in  cervical  cancer  appears  to  be
redictive  of  recurrence.  The  inﬂuence  of  recurrence  or  per-
istence  of  viral  (viral  DNA  or  mRNA)  infection  on  relapse
s  not  known;  it  may  be  hypothesized  that  recurrence  or
ersistence  of  oncogenic  HPV  infection  after  treatment
or  oropharyngeal  carcinoma  is  predictive  of  locoregional
ecurrence.
erspectives
he  number  of  HPV-related  oropharyngeal  carcinomas  is
onstantly  rising  and  the  physiopathology  of  cervical  cancer
an  be  transposed  to  oropharyngeal  cancer,  with  persistent
iral  infection  inducing  genetic  changes  then  cell  transfor-
ation.  Persistent  HPV  infection  of  the  head  and  neck,
owever,  is  at  present  poorly  understood.  Biological  prog-
ostic  factors  identiﬁable  at  diagnosis  and  follow-up  of
ropharyngeal  carcinoma  would  be  of  great  use.  High-risk
PV  is  a  prognostic  factor  that  will  very  probably  soon
e  used  to  optimize  indications  for  radiochemotherapy  or
hemotherapy  in  these  tumors.  It  is  now  indispensable  to
erform  stratiﬁcation  according  to  HPV  status  and  include
hese  patients  in  randomized  prospective  studies  so  as  to
etermine  stratiﬁcation-based  treatment  attitudes.  More-
ver,  ﬁner  substratiﬁcation  (p53,  p16,  EGFR,  etc.)  should
urther  reﬁne  indications.  It  is  also  essential  to  under-
tand  the  mechanisms  involved  in  variable  response  to
adiation  therapy  and  radiochemotherapy  according  to  HPV
tatus  so  as  to  determine  adjuvant  treatments  to  optimize
esponse.
The  relation  of  cervical  cancer  to  HPV  is  now  clearly
stablished.  A  policy  of  vaccination  for  girls  has  been  imple-
ented  for  the  last  5  years  to  prevent  high-risk  HPV-16  and
8  infection  and  the  onset  of  associated  precancerous  and
ancerous  lesions  of  the  cervix  (Gardasil®,  Sanoﬁ-Pasteur-
SD,  Cervarix®,  GSK)  and  genital  lesions  related  to  HPV-6
nd  11  (Gardasil®),  the  two  low-risk  genotypes  implicated
n  90%  of  cases  of  condyloma  acuminatum  and  also  in  respi-
atory  papillomatosis.  The  number  of  oropharyngeal  cancers
elated  to  HPV  infection  is  rising  in  most  western  coun-
ries,  and  the  long-term  aim  should  be  to  reduce  incidence
n  vaccinated  females;  but  this  will  require  many  years’
bservation.  Then  vaccination  could  be  extended  to  males,
s  is  already  the  case  in  certain  countries  to  reduce  the
ncidence  of  HPV-related  male  genital  infection  and  can-
er,  with  the  further  aim  of  reducing  the  incidence  of
PV-related  head  and  neck  infection  and  cancer  if  the
accines  prove  effective  in  preventing  oropharyngeal  infec-
ion.
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